Empowering Targeted Therapy: Lessons from Rituximab
- 13 July 2004
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (241), pe30-30
- https://doi.org/10.1126/stke.2412004pe30
Abstract
Rituximab, a monoclonal antibody directed against the B cell–specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects. Effective as a single agent against some forms of B cell lymphoma, rituximab also has a chemosensitizing effect, enhancing the efficacy of chemotherapy against other forms of the disease. Although the mechanisms whereby rituximab achieves its effects remain incompletely understood, these seem to involve at least three distinct phenomena: (i) antibody-dependent cell-mediated cytotoxicity, (ii) complement-mediated cell lysis, and (iii) stimulation of apoptosis in target cells. The latter occurs through interaction of complexes of rituximab and CD20 in lipid rafts, with elements of a signaling pathway involving Src kinases. Effector molecules trigger various gene expression events, leading to sensitization of malignant cells to proapoptotic stimuli. Lessons learned from the research on rituximab may be applied to the rational development of antibody-based therapies against other forms of cancer.Keywords
This publication has 52 references indexed in Scilit:
- Novel therapies for chronic lymphocytic leukemiaBlood Reviews, 2004
- The CD20 Calcium Channel Is Localized to Microvilli and Constitutively Associated with Membrane RaftsPublished by Elsevier BV ,2004
- Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistanceOncogene, 2004
- Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood, 2004
- FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood, 2004
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and VinorelbineCancer Biotherapy & Radiopharmaceuticals, 2002
- Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal AntibodyJapanese Journal of Cancer Research, 1998
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982